Lupin to lanch Ciprofloxacin generic in the US
The medicine is used for treating bacterial infections.
New Delhi, June 13, 2014: The Indian drug firm Lupin Ltd has launched the generic version of Ciprofloxacin in the US. It may be noted here that the medicine is used for treating bacterial infections.
The company is expecting 180 days of market exclusivity. The launch has been done by the US subsidiary of the company, Lupin Pharmaeuticals Inc (LPI) in the strengths of 5g/100 ml (250mg/5 ml) and 10g/100 ml (500 mg/5 ml).
The company said in a statement that it has already received final approval for the product from the USFDA and it is the first applicant to file an Abbreviated New Drug Application (ANDA) for Cipro oral suspension in 250 mg/ml & 500 mg/ml and as such is entitled to 180 days of marketing exclusivity.
The product has annual US sales of US$ 8.6 million, according to the IMS MAT March 2014 data.